SCHEMBL6442328

SCHEMBL6442328

N#Cc1c(OCCc2ccccn2)nc(N)nc1-c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 3/20 0.39
ADORA1 P30542 6/20 0.39
ADORA2A P29274 5/20 0.39
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MGMT P16455 1/20 0.37
HRH1 P35367 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 2/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 2/20 0.36
HCRTR1 O43613 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443675 0.88 MGMT (0.48) SQORADORA1ADORA2AKDM4EALOX15
SCHEMBL6443629 0.85 ADORA1 (0.57) SQORADORA1ADORA2A
SCHEMBL6448502 0.84 ADORA2A (0.53) SQORADORA1ADORA2AKDM4EHRH1
SCHEMBL5040411 0.84 ADORA2A (0.54) ADORA1ADORA2AKDM4EALDH1A1GLA
SCHEMBL6443184 0.83 ADORA2A (0.56) SQORADORA1ADORA2AKDM4EL3MBTL1
SCHEMBL5131292 0.82 ADORA2A (0.38) ADORA1ADORA2AMGMTSMN1; SMN2POLB
SCHEMBL5132652 0.82 ADORA1 (0.58) SQORADORA1ADORA2A
SCHEMBL5132991 0.82 ADORA1 (0.39) ADORA1ADORA2AKDM4EMGMTALDH1A1
SCHEMBL5133351 0.81 TLR7 (0.38) ADORA1ADORA2AKDM4EALDH1A1GLA
SCHEMBL6441928 0.81 ADORA1 (0.46) ADORA1ADORA2AKDM4EALOX15L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 SQOR 798/4885ADORA1 3/4885ADORA2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.